Topic
2026 HCC Creator Weekend™
Podcasts
Vascular & IR # 659Jun 30, 2026Combination Therapy for Hepatocellular Carcinoma
How do you safely combine locoregional and systemic therapies to treat hepatocellular carcinoma (HCC) when traditional guidelines suggest your hands are tied? In this episode of the 2026 HCC Creator Weekend™, medical oncologist Dr. Lingling Du (Ochsner Health) and interventional radiologist Dr. Beau Toskich (Mayo Clinic Florida) join Dr. Tyler Sandow to break down patient selection, timing strategies, and the practical application of clinical trial outcomes when integrating Y90 radioembolization and immunotherapy in HCC management.
- Vascular & IR # 657Jun 23, 2026
Advanced Techniques in Y90 Cancer Treatment
What do you do when Y-90 doesn’t deliver the results you expected? In this episode of the 2026 HCC Creator Weekend™, host Dr. Tyler Sandow is joined by Drs. Beau Toskich and Juan Gimenez to discuss the technical challenges and troubleshooting strategies that can make or break a Y-90 radioembolization case. Together, they explore innovative approaches like the PREDATr technique, share tips for reducing complications, and offer guidance on optimizing outcomes for patients with complex liver tumors.
- Vascular & IR # 655Jun 16, 2026
Managing Large Liver Tumors: Strategies & Challenges
How is Y90 radioembolization rewriting the rules for managing large HCC tumors and creating new curative-intent therapeutic pathways where palliation was once deemed the only option? In this episode of the 2026 HCC Creator Weekend™, interventional radiologists Dr. Chris Malone (WashU), Dr. Tyler Sandow (Ochsner Health), and Dr. Beau Toskich (Mayo Clinic Florida) join host Dr. Zach Berman for a case-based discussion on advanced dosimetric strategies and embolization approaches for large and complex HCC lesions.
- Vascular & IR # 653Jun 9, 2026
Radiation Lobectomy Techniques & Downstaging for HCC
How can targeted liver radiation unlock surgical or transplant options for tough hepatocellular carcinoma (HCC) cases? In this episode of the BackTable 2026 HCC Creator Weekend™, host Dr. Kavi Krishnasamy is joined by interventional radiologists Dr. Beau Toskich and Dr. Chris Malone to explore how downstaging and radiation lobectomy with Y90 are creating new surgical and transplant opportunities for patients with limited future liver remnants. They discuss Y90’s role as a “test of time” for tumor biology, strategies to prevent post-hepatectomy liver failure, and the ongoing challenge of recurrence even after R0 resection in cirrhotic livers.
- Vascular & IR # 651Jun 2, 2026
Radioembolization Workflow: Insights & Best Practices
What does it really take to run a high-volume Y90 program that is efficient, scalable, and patient-centered? In this episode of the BackTable 2026 HCC Creator Weekend™, host Dr. Zach Berman is joined by Drs. Nima Kokabi and Kirema Garcia-Reyes to break down the systems, workflows, and strategies that drive successful radioembolization centers. The conversation focuses on overcoming referral and insurance delays, implementing multidisciplinary clinics, and using tools like single-session Y90 and routine post-treatment dosimetry to reduce treatment times and improve outcomes.
- Vascular & IR # 649May 27, 2026
Y90 Radioembolization Dosimetry: Techniques & Challenges
Can the right dosimetry approach turn palliative Y90 into a curative therapy? In this episode of the BackTable 2026 HCC Creator Weekend™, interventional oncologists Dr. Riad Salem, Dr. Nima Kokabi, and Dr. Zach Berman examine modern Y90 dosimetry, from the decline of body-surface-area calculations to newer strategies that tailor treatment intensity to tumor burden, liver reserve, and clinical intent.
Tumor Board # 59May 12, 2026Evolving Treatment Paradigms in Hepatocellular Carcinoma: What's on the Horizon?
With new systemic and liver-directed approaches under investigation, which targets and treatment strategies are most likely to shape HCC care? In this final episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi focus on the future of hepatocellular carcinoma beyond established PD-1/CTLA-4 regimens.
- Vascular & IR # 644May 12, 2026
Optimizing Liver Transplant Pathways & Decision-Making
A high-functioning HCC tumor board can turn complex transplant decisions into coordinated treatment plans that account for liver reserve, tumor biology, and evolving biomarkers. In this episode of the BackTable Podcast 2026 HCC Creator Weekend™, abdominal transplant surgeon Dr. Ari Cohen (Ochsner Health) and transplant hepatologist Dr. Neil Mehta (UCSF) join host Dr. Kavi Krishnasamy to map out strategies for effective multidisciplinary treatment and transplantation planning in HCC.
- Vascular & IR # 642May 7, 2026
Exploring CPN & Radiation Segmentectomy in Liver Cancer
Complete pathologic necrosis (CPN) rates above 90%? This week’s BackTable episode from the 2026 HCC Creator Weekend™ is cracking the code on complete tumor kill in hepatocellular carcinoma (HCC) bridging therapy. Host Dr. Kavi Krishnasamy is joined by Dr. Zach Berman and Dr. Beau Toskich to break down the latest multi-center research from COBRAS (Consortium on Bridging Radiation Segementectomy with Glass Microspheres Before Transplant), setting a new standard for bridging therapy that offers actionable strategies to improve outcomes.
- Vascular & IR # 641May 5, 2026
Understanding BCLC Updates & Guidelines
With recent updates to the Barcelona Clinic Liver Classification (BCLC), how should multidisciplinary teams adapt their treatment strategies to accommodate the newest evidence? In this episode of the BackTable Podcast 2026 HCC Creator Weekend™, Dr. Neil Mehta of UCSF and Dr. Riad Salem of Northwestern Medicine join host Dr. Tyler Sandow to explore the complexities of hepatocellular carcinoma (HCC) therapies and the practical application of the latest global algorithms in balancing standardized therapeutic algorithms with individual patient factors.
- Tumor Board # 58May 5, 2026
Advanced Hepatocellular Carcinoma: Navigating Second-Line Therapy Options
When first-line treatment for advanced hepatocellular carcinoma (HCC) fails and the disease progresses, what options are available for second-line therapy? In this episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi explore the uncertain landscape of second-line treatment after first-line immunotherapy, such as atezolizumab and bevacizumab or the STRIDE regimen, including practical considerations for choosing which second-line therapy to use.
- Vascular & IR # 639Apr 30, 2026
Advancements in Ablation Techniques for Liver Tumors
Why settle for “good enough” ablation margins when today’s tools can deliver more and decrease the risk of recurrence? Host Dr. Kavi Krishnasamy sits down with interventional radiologists Dr. Christopher Malone (WashU, St. Louis) and Dr. Kirema Garcia-Reyes (Mount Sinai, NYC) at our 2026 HCC Creator Weekend™ in-studio in New Orleans to discuss modern liver ablation strategies for HCC and metastatic disease. The conversation centers on challenging real-world cases, combining multidisciplinary tumor board insights with hands-on experience using ablation confirmation software, radiofrequency, cryo, and microwave ablation.
- Tumor Board # 57Apr 28, 2026
First-Line Therapy for Advanced Hepatocellular Carcinoma: Decisions in the Real World
Learn how a “watershed” clinical trial in 2020 completely overturned a decade of standard care for liver cancer. In this inaugural episode of the BackTable 2026 HCC Creator Weekend™ , medical oncologists Dr. John Rahi, Dr. Craig Lockhart, and Dr. Lingling Du review the evolution of first-line systemic therapy for hepatocellular carcinoma (HCC), highlighting immune checkpoint inhibitors as a major change from the TKI era.